Nippon Shinyaku Co., Ltd.
FY2026 Q3 Financial Summary〔IFRS〕(Consolidated)
For the third quarter of FY2026, revenue was JPY 127.135 billion (4.8% YoY increase) and operating income was JPY 32.333 billion (1.3% YoY decrease), leading to an upward revision of full-year revenue guidance by 1.2%.
Key Figures
- Revenue: JPY 127.135 billion (4.8% YoY increase)
- Operating Income: JPY 32.333 billion (1.3% YoY decrease)
- Net Income Attributable to Owners of Parent for the Quarter: JPY 25.844 billion (9.5% YoY decrease)
AI要約
Performance Overview
Consolidated Q3 revenue for FY2026 was JPY 127.135 billion, a 4.8% increase year-on-year. Despite price revisions and generic drug impacts in the pharmaceuticals segment, sales growth of 5.4% was supported by contributions from 'Uptravi,' 'Fintepla,' and the newly recognized product sales of 'Alliday.' The functional foods segment also increased by 1.1% due to higher sales of health food ingredients and supplements. Operating income declined by 1.3% year-on-year to JPY 32.333 billion due to increased SG&A expenses, and net income attributable to owners of the parent decreased 9.5% to JPY 25.844 billion.
Financial Position and Cash Flow
Total assets increased by JPY 44.47 billion from the previous consolidated fiscal year-end to JPY 328.108 billion, and total equity rose by JPY 36.856 billion to JPY 284.196 billion. Cash flow from operating activities generated inflows of JPY 12.002 billion, investing activities generated inflows of JPY 1.518 billion, and financing activities resulted in outflows of JPY 9.24 billion.
Revision of Consolidated Earnings Forecast
The full-year consolidated earnings outlook for FY2026 was revised upward based on changes in assumed exchange rates, revising revenue to JPY 170 billion (1.2% increase from previous forecast). There were no changes to the outlook for operating income, profit before tax, or net income attributable to owners of the parent.
Research and Development Status
Development is progressing domestically and internationally for multiple pharmaceuticals. Key focus products include Duchenne muscular dystrophy treatment 'Viltepso,' blastic plasmacytoid dendritic cell tumor treatment 'NS-401,' and epilepsy treatment 'Fintepla.' Efforts overseas include responses to FDA reviews and continuation of clinical trials.
Contingent Liability Litigation Status
In a U.S. patent lawsuit, the jury upheld Sarepta Therapeutics' patent validity. Nippon Shinyaku is considering an appeal and has not recorded any provision for damages.
